newsfilter
← Latest News
PR Newswire·

Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)

Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause More than half of women ages 40 to 64 worldwide experience VMS, with rates in Europe ranging from 56% to